Close Menu

Venture capital firms are largely staying away from biotech, says Forbes' Bruce Booth. Reduced capital is a cyclical issue, and even with the problems in the biotech sector, bioentrepreneurs are still raising billions of dollars, he says. But what's really concerning is that the number of venture firms investing in biotech is shrinking and they're becoming less diverse.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.